Skip to content
Study details
Enrolling now

A Study of LY4088044 in Healthy Participants

Eli Lilly and Company
NCT IDNCT07090785ClinicalTrials.gov data as of Apr 2026
Phase

Phase 1

Target enrollment

104

Study length

about 2 years

Ages

18–65

Locations

4 sites in CA, KS, TX +1

What this study is about

This trial is testing a new drug called LY4088044 to see how well it's tolerated and what side effects might occur. The drug will be given either under the skin or into a vein, and blood tests will monitor its levels and elimination from the body. It lasts up to 92 weeks.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Take LY4088044
  • 2.Take Placebo

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Standard

How treatment is administered

Treatment Assignment
Randomized & Blinded

You may get a placebo/standard care, and you won't know which.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Endpoints

Primary: Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration

Secondary: PK: Area Under the Concentration Versus Time Curve (AUC) of LY4088044, Pharmacodynamics (PD): Protein Levels in Skin Samples, Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY4088044